Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers track rare colorectal cancer subtype to improve treatment decisions

NCT ID NCT05511688

Knowledge-focused Sponsor: Federation Francophone de Cancerologie Digestive Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 637 people with a specific type of colorectal cancer called microsatellite instability (MSI). The goal is to identify factors that predict how the cancer will behave and whether chemotherapy helps. By collecting clinical and molecular data, researchers hope to better guide treatment for both early and advanced stages of this cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which patients with this type of colorectal cancer need chemotherapy and which do not.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly provide new therapies. Results may take years and might not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

637 people

The number who actually took part.

Started

Mar 2017

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with MSI colrectal cancers (stage I to IV)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with MSI colorectal cancer defined either by molecular biology (more than 30% of microsatellites tested unstable) or by immunohistochemistry (loss of expression of at least one MMR protein: MLH1, MSH2, MSH6, PMS2) * Histologically proven colorectal cancer diagnosed on or after January 1 of the cohort start date * Stage I, II, III (non-metastatic) or IV (metastatic) Exclusion Criteria: * Colorectal cancer MSS * Contraindication due to psychological, social, or geographical reasons that may hinder patient follow-up * Opposition of the patient to registration in the cohort * Stage 0 (Tumor in situ, N0, M0)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Microsatellite Instability

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Microsatellite instability

Contacts and locations

Locations

  • CH

    Angoulême, France

  • CH

    Abbeville, France

  • Ch - Centre Hospitalier de Bézier

    Béziers, France

  • Ch - Ght Unyon Auxerre

    Auxerre, France

  • Ch - Hôpital Henri Duffaut

    Avignon, France

  • Ch - Hôpital Victor Dupouy

    Argenteuil, France

  • Chu - Hôpital Hôtel Dieu

    Angers, France

  • Chu - Hôpital Jean Minjoz

    Besançon, France

  • Chu - Hôpital Sud

    Amiens, France

  • Chu Poitiers

    Poitiers, VIENNE, 86021, France

  • Privé - Clinique Tivoli

    Bordeaux, France

  • Privé - Institut Du Cancer Avignon Provence

    Avignon, France

  • Privé - Polyclinique Bordeaux Nord

    Bordeaux, France

  • Privé- Centre Pierre Curie

    Beuvry, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.